Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab plus Cemiplimab in RRMM
NCT03194867Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2018
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of cemiplimab in multiple myeloma (MM) (3 arms), sponsored by Sanofi. Primary endpoints: Dose-Limiting Toxicities, Treatment-Emergent Adverse Events and 1 more. Started Feb 2018; status: completed.
02
Drugs
cemiplimab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03194867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03194867.